| Ulcerative Colitis
Remicade vs Uceris
Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.Deep comparison between: Remicade vs Uceris with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUceris has a higher rate of injection site reactions vs Remicade based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Uceris but not Remicade, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Remicade
Uceris
At A Glance
IV infusion
Every 8 weeks
TNF-alpha inhibitor
Rectal foam
Twice daily, then once daily
Glucocorticosteroid
Indications
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Psoriasis vulgaris
- Ulcerative Colitis
Dosing
Crohn Disease, Ulcerative Colitis 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks (adults and pediatric patients >= 6 years).
Rheumatoid Arthritis 3 mg/kg IV induction at 0, 2, and 6 weeks, then 3 mg/kg every 8 weeks in combination with methotrexate; dose may be increased up to 10 mg/kg every 8 weeks or every 4 weeks for incomplete responders.
Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks.
Ulcerative Colitis 1 metered dose administered rectally twice daily for 2 weeks, followed by 1 metered dose administered rectally once daily for 4 weeks.
Contraindications
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab, any inactive ingredient of REMICADE, or any murine proteins (including anaphylaxis, hypotension, and serum sickness)
- History of known hypersensitivity to budesonide or any ingredient of UCERIS rectal foam, including anaphylaxis
Adverse Reactions
Most common (>10%) Infections (upper respiratory tract infection, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain.
Serious Pneumonia, cellulitis, abscess, sepsis, bacterial infection, hepatotoxicity, acute liver failure, malignancies (including lymphoma), pancytopenia, thrombocytopenia, leukopenia.
Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, peripheral demyelinating disorders, anaphylactic shock, cerebrovascular accidents, myocardial ischemia/infarction.
Most common (>=2%) Decreased blood cortisol, adrenal insufficiency, nausea
Serious Hypercorticism and adrenal axis suppression, steroid withdrawal symptoms, increased susceptibility to infection, other glucocorticosteroid effects
Postmarketing Hypertension, pancreatitis, pyrexia, peripheral edema, anaphylactic reactions, dizziness, benign intracranial hypertension, mood swings, pruritus, maculopapular rash, allergic dermatitis
Pharmacology
TNF-alpha antagonist; infliximab is a chimeric IgG1 monoclonal antibody that neutralizes the biological activity of TNF-alpha by binding with high affinity to both soluble and transmembrane forms of TNF-alpha and inhibiting its binding to receptors, thereby reducing inflammation in RA, CD, UC, AS, PsA, and Ps.
Budesonide is a synthetic non-halogenated glucocorticosteroid that exerts local anti-inflammatory activity via glucocorticosteroid receptor binding; it undergoes extensive first-pass hepatic metabolism via CYP3A4, resulting in low systemic bioavailability.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Remicade
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (0/12)
Uceris
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Remicade
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Uceris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Remicade
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Uceris
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Remicade.
No savings programs available for Uceris.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RemicadeView full Remicade profile
UcerisView full Uceris profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.